How to transition a patient with type 2 diabetes mellitus (T2DM) from daily glipizide (sulfonylurea) to a Glucagon-Like Peptide-1 (GLP-1) receptor agonist?
[DOI] [PubMed] [Google Scholar] 75.van Witteloostuijn SB, Pedersen SL, Jensen KJ
Some surrogates choose to provide breast milk for the intended parents for a period after birth
The picture is complicated by several confounding factors: Weight loss itself is associated with improved mood and reduced depressive symptoms in many individuals Better glycaemic control may enhance overall wellbeing and reduce diabetes-related distress Selection bias may exist, as patients with severe mental health conditions might be less likely to be prescribed these medications initially Currently, there is no official indication for GLP-1 agonists in treating depression, and the MHRA has not licensed these medications for mental health conditions
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial
227 Determining whether GLP-1 has direct/indirect effects on islet alpha-cells and what receptor(s) mediate these actions requires further investigation
-1775582746855.png&w=3840&q=75)
